Cellular ‘Roads’ Found to Actively Transmit Signals, Opening New Avenues for Medical Intervention
Table of Contents
A groundbreaking study has revealed that microtubules – the structural components within cells often likened to a city’s road network – aren’t just passive conduits for cellular commands, but actively participate in signal transmission, potentially revolutionizing our understanding of cell function and opening new therapeutic possibilities.
Microtubules: More Than Just Cellular Infrastructure
For decades, scientists understood that signalling proteins orchestrate a vast array of cellular processes, from division and growth to immune response and programmed cell death. These signals typically originate outside the cell, binding to receptors on the cell membrane and initiating a cascade of events that ultimately reach the cell’s interior. Microtubules, forming the cytoskeleton, were believed to primarily receive these signals, adjusting their structure in response. However, recent research demonstrates they also transmit signals, acting as crucial intermediaries in cellular communication.
“They complete our picture of the signalling cascades triggered in the cell by messenger substances such as hormones and cytokines,” explained a senior researcher involved in the study. “As an active element in this mechanism, microtubules assume an even greater significance.”
Unlocking the Molecular Mechanism: The Role of GEFH1 and the C1 Domain
A team at the Paul Scherrer Institute (PSI) Center for Life Sciences, led by Sung Choi and Michel Steinmetz, has pinpointed a key protein, GEFH1 (guanine nucleotide exchange factor H1), as central to this signal transmission process. GEFH1 activates the RhoA signalling pathway, a critical regulator of cell division, motility, and wound healing.
The team discovered that GEFH1 binds to microtubules via a specific region known as the C1 domain. “We bioengineered and tested fragments of GEFH1 that are capable of binding to microtubules,” Choi reported. “This allowed us to clearly establish that the C1 domain alone is responsible for the binding.” Using cryo-electron microscopy, researchers visualized how the C1 domain fits precisely into a recess formed by four tubulin proteins – the building blocks of microtubules – much like a plug into a socket.
This binding isn’t permanent. When the microtubule dynamically unravels, releasing GEFH1, the RhoA signalling pathway is activated, initiating further cellular processes.
Implications for Cancer Treatment and Beyond
This discovery has significant implications for medicine. Current therapies often target receptors on the cell membrane to block signals that promote uncontrolled cell growth in cancer, or to enhance immune responses. The identification of the C1 domain as a key interaction point opens up a new avenue for intervention.
“We would then have an additional tool to intervene to address malfunctions,” stated a lead investigator.
The relevance extends beyond GEFH1. Researchers believe many other signalling proteins utilize C1 domains to interact with microtubules, potentially expanding the range of therapeutic targets. Notably, the study also highlighted the role of RASSF1A, a tumor suppressor protein, which also interacts with microtubules via the C1 domain. RASSF1A is frequently inactivated in over 40 types of human cancers, including lung, breast, and prostate cancer, underscoring the potential of targeting this mechanism.
Future Research and Expanding the Understanding
While the study focused on C1 domain-mediated binding, researchers acknowledge that other signalling proteins may interact with microtubules through different mechanisms. “How they do this is something we want to find out in further studies,” said Steinmetz. “To that end, we have developed a pipeline of tests and procedures that can be transferred to the task of tracking down additional mechanisms.”
The PSI team’s findings represent a fundamental advance in our understanding of cellular signalling, paving the way for the development of more targeted and effective therapies for a wide range of diseases. .
